A clinical-stage biopharmaceutical company focused on developing therapies for acute gastrointestinal complications and inflammatory conditions. Its lead drug candidates target postoperative digestive dysfunction and other GI disorders, areas with limited treatment options. Investors track the compa...
1 member of Congress has disclosed 1 trade in Pali Corp (PALI), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-06-24 | JOHN K. DELANEY | sell | $15K – $50K |